INmune Bio stock sits 36.15 percent below its Nasdaq high

Published on 10/15/2026 at 19:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

INmune Bio held USD 46.1 million market value on October 15, 2026. INmune Bio stock costs EUR 1.48 on October 15, 2026, up 3.75 percent versus Nasdaq's prior close.

Valuation and price context

Nasdaq trading stood 36.15 percent below the 52-week high on October 15, 2026.
INmune Bio carried a USD 46.1 million market capitalization as of October 15, 2026.
INmune Bio stock costs EUR 1.48 at Lang & Schwarz on October 15, 2026 at 7:34 p.m. CEST; Nasdaq trading was 3.75 percent above the prior close of October 14, 2026.
INmune Bio posted a trailing price-to-earnings ratio of minus 2.40 as of October 15, 2026.

INMB, US45782T1051, Illustration mit AI erstellt.

INmune Bio stock stood 36.15 percent below its Nasdaq 52-week high on October 15, 2026, based on a home-market price of USD 1.66 against a USD 2.60 high. The stock's euro quotation was EUR 1.48 at Lang & Schwarz at 7:34 p.m. CEST, while Nasdaq trading was 3.75 percent above the prior close of October 14, 2026.

Range leaves room above the low

The Nasdaq 52-week range ran from USD 1.09 to USD 2.60 on October 15, 2026. At USD 1.66, INmune Bio was 52.29 percent above the low and 36.15 percent below the high, putting the current home-market price nearer the lower end of the annual band.

The intraday Nasdaq range extended from USD 1.53 to USD 1.68 on October 15, 2026, with an opening price of USD 1.58. Trading volume reached 581,687 shares against an average volume of 351,412 shares, giving the session a concrete liquidity reference for investors following the move.

Valuation remains loss-making

INmune Bio had a market capitalization of USD 46.1 million as of October 15, 2026. Its trailing price-to-earnings ratio was minus 2.40 and its dividend yield was 0.00 percent, reflecting a company that was still loss-making rather than an established income stock.

For comparison, Sana Biotechnology traded at USD 2.45 on October 15, 2026, up 5.15 percent, with a price-to-earnings ratio of minus 3.26 and a USD 733.4 million market capitalization. MiMedx Group traded at USD 4.70, up 0.08 percent, with a price-to-earnings ratio of 117.63 and a USD 685.6 million market capitalization.

Comparison with peers

INMB (Nasdaq, USD): 3.75 percent, P/E minus 2.40, market capitalization USD 46.1 million

Sana Biotechnology (Nasdaq, USD): 5.15 percent, P/E minus 3.26, market capitalization USD 733.4 million

MiMedx Group (Nasdaq, USD): 0.08 percent, P/E 117.63, market capitalization USD 685.6 million

Euro price after hours

The euro quotation places the German trading perspective below the stock's annual high, while the Nasdaq session provides the comparable same-day move. The price at Lang & Schwarz was EUR 1.48 on October 15, 2026 at 7:34 p.m. CEST; Nasdaq trading was 3.75 percent above the prior close of October 14, 2026.

The further course of trading is shown by the continuously updated real-time quote of INmune Bio stock.